Phase 3 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People diagnosed with acute myeloid leukemia (AML) that did not respond to initial treatment (called primary refractory AML)
- People diagnosed with AML that came back shortly after treatment ended (called early relapsed AML)
- People who have signed a consent form agreeing to take part in the study
Who may not be able to join:
- People whose AML came back a long time after treatment ended (late relapsed AML)
- People whose AML has returned only in areas outside the bone marrow, with no involvement of the bone marrow itself
- People who have signs of returning disease only detectable by sensitive lab tests, without full bone marrow relapse
- People diagnosed with a specific type of leukemia called acute promyelocytic leukemia
- People whose leukemia previously stopped responding to a drug called venetoclax
- People who have previously received a bone marrow or stem cell transplant from a donor
- People who are pregnant or breastfeeding
- People of childbearing potential who are unwilling to use highly effective contraception throughout the study
- People who have not signed the required consent form
- People who are unable or unwilling to follow the study's requirements
- People currently participating in another clinical trial
- People with infections that are not under control
- People whose overall physical condition is rated as ECOG 3 or higher, meaning they have significant limitations in daily activity (confirm with trial site)
- People who have had another cancer within the past 3 years, with some exceptions for certain treated skin cancers and non-invasive cancers that the doctor considers low risk of returning
- People with severe kidney disease where the kidneys are functioning at a very low level (GFR of 30 or below, measured by a specific formula)
- People with serious heart conditions, including: uncontrolled high blood pressure; moderate-to-severe chest pain on exertion (angina); a recent heart attack or unstable chest pain within the past 6 months; significant heart failure; or uncontrolled irregular heart rhythms or major abnormalities on a heart tracing (ECG)
- People with advanced liver scarring (cirrhosis rated as Class B or C using a standard medical scale)
- People with significantly elevated liver test results above certain thresholds (confirm specific values with trial site)
- People who have had major surgery within the 14 days before joining the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +79629087553
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival of patients with R/R AML depending on the use of high or low intensity therapy exposure before alloHSCT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.